Back to Journals » Breast Cancer: Targets and Therapy » Volume 10

Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date [Corrigendum]

Authors Criscitiello C, Viale G, Curigliano G, Goldhirsch A

Received 21 February 2018

Accepted for publication 21 February 2018

Published 16 March 2018 Volume 2018:10 Pages 51—52

DOI https://doi.org/10.2147/BCTT.S166117


Criscitiello C, Viale G, Curigliano G, et al. Profile of
buparlisib and its potential in the treatment of breast cancer:
evidence to date. Breast Cancer (Dove Med Press).
2018;10:23–29.

On page 23, Giuseppe Curigliano’s affiliation was incorrcectly
listed as European Institute of Oncology, Milan, Italy.
It should be Department of Oncology and Hemato-Oncology,
Division of Early Drug Development for Innovative Therapy,
University of Milan, European Institute of Oncology, Milan,
Italy.

Read the original article

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]